ArticleEsophagus : official journal of the Japan Esophageal Society2026
Correlation of growth differentiation factor 15 level in esophageal cancer with cachectic indicators and postoperative infectious complication.
Article in Esophagus : official journal of the Japan Esophageal Society, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed, 1 synthesis or guideline pooled it.
- Biomarkers associated with post-operative pneumonia: a systematic review and meta-analysis.BMC pulmonary medicine · 2026Pooled it
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
backgroundPatients with esophageal cancer (EC) usually have multiple comorbidities, particularly, high cachexia incidence, which may lead to increased postoperative complications. A novel inflammatory marker, growth differentiation factor 15 (GDF15), was recently reported to be associated with cancer cachexia. This study evaluated the correlation between clinical data suggestive of cachexia in patients with EC and circulating GDF15 levels.
methodsEighty patients with EC were enrolled in this study. Plasma samples were collected before initiating any cancer treatment. GDF15 was quantified using ELISA. Clinical information, including age, comorbidities, biochemical data, Controlling Nutritional Status score, and Psoas muscle index (PMI), was collected from the clinical records. Clinical impact of GDF15 was then evaluated and compared with cachectic indicators or postoperative results.
resultsThe median value of GDF15 was 1168 pg/mL (range 298-9100 pg/mL). GDF15 values statistically correlated with age, prevalence of diabetes, serum level of aspartate aminotransferase/γ-glutamyltransferase/creatinine/blood sugar/albumin, and PMI. Sixty-three patients finally underwent curative esophagectomy with right thoracic approach and gastric tube reconstruction. Patients with infectious complications had a statistically higher GDF15 than those without. The cut-off value was 930 pg/mL for detecting infectious complications, with an area under the receiver operating characteristic curve value of 0.685, and high GDF15 was detected as an independent risk factor for postoperative infectious complications.
conclusionsGDF15 is potentially suggestive of general condition deterioration from aging, organ dysfunction, and decreased muscle mass, which may lead to cachexia in patients with EC. Moreover, patients with higher GDF15 are at a risk of postoperative infectious complications.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.